Tesla Stock: Q2 Ended Robot Romance
Tesla faces significant program delays in robotaxi and humanoid robots, undermining its first-mover advantage and premium valuation. Q2 '26 results showed a big EPS miss, heavy capex of $5.8B, and negative free cash flow, despite a revenue beat.
Intelligence analysis by Llama
Tesla's Q2 results were disappointing, with a big EPS miss and further delays in key programs. The company's aggressive spending on unproven products and lack of near-term revenue visibility from major robotaxi and robots catalysts make it a stock to avoid.
Imagine you're building a new car, but you're not sure if it will be good or not. You're spending a lot of money on it, but you're not making any money back yet. That's kind of like what's happening with Tesla. They're building new cars, but they're not sure if they'll be successful, and they're spending a lot of money on it. This makes it a riskier investment.
Analysis
A $60B Vote of Confidence, Now in Question
Tesla's Q2 results were a disappointment, with a big EPS miss and further delays in key programs. The company's aggressive spending on unproven products and lack of near-term revenue visibility from major robotaxi and robots catalysts make it a stock to avoid. The market was disappointed by weak profitability, a $0.21 EPS miss, and further delays in robotaxi and humanoid robot programs, eroding confidence in future growth.
Why Cursor?
The company's capex surged to $5.8B in Q2 with plans to exceed $25B, resulting in negative free cash flow. This amplifies risk given unproven product readiness and delayed catalysts. Tesla's valuation remains highly expensive at 170x forward EPS, with its valuation still pricing in substantial success from delayed robotaxi and humanoid robot initiatives that lack near-term revenue visibility.
The Road Ahead
Tesla's current valuation is not justified given its business outlook. The company's premium valuation and delayed growth drivers make it a stock to avoid for now. The stock should be avoided, trading at 170x forward EPS with delayed growth drivers and heightened execution risk.
Key points
- Tesla's Q2 results were disappointing, with a big EPS miss and further delays in key programs.
- The company's aggressive spending on unproven products and lack of near-term revenue visibility from major robotaxi and robots catalysts make it a stock to avoid.
- Tesla's valuation remains highly expensive at 170x forward EPS, with its valuation still pricing in substantial success from delayed robotaxi and humanoid robot initiatives that lack near-term revenue visibility.
If Tesla can successfully launch its robotaxi and humanoid robot programs, it could lead to significant growth and increased revenue. However, this is still a long way off, and the company's current valuation is not justified given its business outlook.
If Tesla's delays in key programs continue, it could lead to a further decline in its valuation and a loss of investor confidence. The company's aggressive spending on unproven products and lack of near-term revenue visibility from major robotaxi and robots catalysts make it a stock to avoid.
